NIH launches discussion of in utero gene therapy...and seeks to repair 'flaw' in review process.
M
M
Wadman
D026683:Advisory Committees; D004274:DNA, Recombinant; D035082:Federal Government; D005315:Fetal Diseases / Q000628:therapy*; D015316:Genetic Therapy / Q000009:adverse effects; D033161:Government Regulation; D017408:Guidelines as Topic; D006801:Humans; D009316:National Institutes of Health (U.S.); D037841:Pregnant People; D011640:Public Policy; D018570:Risk Assessment; D016511:Severe Combined Immunodeficiency / Q000196:embryology / Q000628:therapy; D014481:United States; D014486:United States Food and Drug Administration; D017085:alpha-Thalassemia / Q000196:embryology / Q000628:therapy
D004274:DNA, Recombinant